Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of oral GH55 in MAPK pathway-mutant advanced solid tumors
CTR20222761Phase 2Active
- Sponsor
- Genhouse Bio
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of GH55 in Nonhematologic neoplasms (8 arms), sponsored by Genhouse Bio. Primary endpoints: Phase I dose-escalation safety and tolerability and Phase II objective response rate. Started Dec 2022; status: active.
02
Drugs
GH55
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20222761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222761.